Phaarmasia（523620）株式概要ファルマシア社はインドで経口避妊薬と鉄剤を製造販売している。 詳細523620 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績3/6財務の健全性4/6配当金0/6報酬株価収益率（ 3 x） Indian市場（ 22.3 x）を下回っています。今年は黒字化を達成 リスク分析Indian市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( ₹523M )財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見る523620 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW479,394 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA479,394 investors already sharing narrativesYour Fair Value₹Current Price₹76.6317.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-19m1b2016201920222025202620282031Revenue ₹1.1bEarnings ₹389.1mAdvancedSet Fair ValueView all narrativesPhaarmasia Limited 競合他社Goldline PharmaceuticalSymbol: BSE:544759Market cap: ₹384.9mBiofil Chemicals and PharmaceuticalsSymbol: BSE:524396Market cap: ₹513.1mShelter PharmaSymbol: BSE:543963Market cap: ₹450.2mZenith DrugsSymbol: NSEI:ZENITHDRUGMarket cap: ₹771.7m価格と性能株価の高値、安値、推移の概要Phaarmasia過去の株価現在の株価₹76.6352週高値₹131.7552週安値₹26.66ベータ0.791ヶ月の変化-17.58%3ヶ月変化-9.31%1年変化176.44%3年間の変化195.87%5年間の変化214.70%IPOからの変化467.63%最新ニュースReported Earnings • Aug 15First quarter 2027 earnings released: EPS: ₹0.50 (vs ₹0.40 in 1Q 2026)First quarter 2027 results: EPS: ₹0.50 (up from ₹0.40 in 1Q 2026). Revenue: ₹85.8m (up 25% from 1Q 2026). Net income: ₹3.39m (up 26% from 1Q 2026). Profit margin: 3.9% (in line with 1Q 2026). Over the last 3 years on average, earnings per share has increased by 130% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.New Risk • Aug 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (327% accrual ratio). Market cap is less than US$10m (₹582.3m market cap, or US$6.10m). Minor Risk Revenue is less than US$5m (₹472m revenue, or US$4.9m).お知らせ • Aug 10Phaarmasia Limited to Report Q1, 2027 Results on Aug 13, 2026Phaarmasia Limited announced that they will report Q1, 2027 results on Aug 13, 2026New Risk • Jun 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (327% accrual ratio). Market cap is less than US$10m (₹750.7m market cap, or US$7.88m). Minor Risk Revenue is less than US$5m (₹472m revenue, or US$5.0m).Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹91.85, the stock trades at a trailing P/E ratio of 3.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 254% over the past three years.Reported Earnings • May 31Full year 2026 earnings released: EPS: ₹25.74 (vs ₹2.33 loss in FY 2025)Full year 2026 results: EPS: ₹25.74 (up from ₹2.33 loss in FY 2025). Revenue: ₹481.7m (up 98% from FY 2025). Net income: ₹175.7m (up ₹191.6m from FY 2025). Profit margin: 37% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 132% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.最新情報をもっと見るRecent updatesReported Earnings • Aug 15First quarter 2027 earnings released: EPS: ₹0.50 (vs ₹0.40 in 1Q 2026)First quarter 2027 results: EPS: ₹0.50 (up from ₹0.40 in 1Q 2026). Revenue: ₹85.8m (up 25% from 1Q 2026). Net income: ₹3.39m (up 26% from 1Q 2026). Profit margin: 3.9% (in line with 1Q 2026). Over the last 3 years on average, earnings per share has increased by 130% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.New Risk • Aug 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (327% accrual ratio). Market cap is less than US$10m (₹582.3m market cap, or US$6.10m). Minor Risk Revenue is less than US$5m (₹472m revenue, or US$4.9m).お知らせ • Aug 10Phaarmasia Limited to Report Q1, 2027 Results on Aug 13, 2026Phaarmasia Limited announced that they will report Q1, 2027 results on Aug 13, 2026New Risk • Jun 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (327% accrual ratio). Market cap is less than US$10m (₹750.7m market cap, or US$7.88m). Minor Risk Revenue is less than US$5m (₹472m revenue, or US$5.0m).Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹91.85, the stock trades at a trailing P/E ratio of 3.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 254% over the past three years.Reported Earnings • May 31Full year 2026 earnings released: EPS: ₹25.74 (vs ₹2.33 loss in FY 2025)Full year 2026 results: EPS: ₹25.74 (up from ₹2.33 loss in FY 2025). Revenue: ₹481.7m (up 98% from FY 2025). Net income: ₹175.7m (up ₹191.6m from FY 2025). Profit margin: 37% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 132% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.お知らせ • May 22Phaarmasia Limited to Report Q4, 2026 Results on May 29, 2026Phaarmasia Limited announced that they will report Q4, 2026 results on May 29, 2026Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹93.49, the stock trades at a trailing P/E ratio of 3.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 253% over the past three years.New Risk • Apr 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹607.2m market cap, or US$6.56m). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₹449m revenue, or US$4.9m).Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹88.94, the stock trades at a trailing P/E ratio of 3.4x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 240% over the past three years.Valuation Update With 7 Day Price Move • Mar 24Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹75.20, the stock trades at a trailing P/E ratio of 2.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 209% over the past three years.Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹99.12, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 304% over the past three years.Reported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹23.84 (vs ₹1.02 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹23.84 (up from ₹1.02 loss in 3Q 2025). Revenue: ₹162.1m (up 243% from 3Q 2025). Net income: ₹162.7m (up ₹169.7m from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 55% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 02Phaarmasia Limited to Report Q3, 2026 Results on Feb 06, 2026Phaarmasia Limited announced that they will report Q3, 2026 results on Feb 06, 2026Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improves as stock rises 33%After last week's 33% share price gain to ₹49.08, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 57% over the past three years.Reported Earnings • Nov 16Second quarter 2026 earnings released: EPS: ₹2.54 (vs ₹0.94 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹2.54 (up from ₹0.94 loss in 2Q 2025). Revenue: ₹166.9m (up 182% from 2Q 2025). Net income: ₹17.4m (up ₹23.8m from 2Q 2025). Profit margin: 10% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 07Phaarmasia Limited to Report Q2, 2026 Results on Nov 14, 2025Phaarmasia Limited announced that they will report Q2, 2026 results on Nov 14, 2025お知らせ • Sep 03Phaarmasia Limited, Annual General Meeting, Sep 25, 2025Phaarmasia Limited, Annual General Meeting, Sep 25, 2025, at 16:00 Indian Standard Time.New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (₹180.9m market cap, or US$2.06m). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (₹230m revenue, or US$2.6m).Reported Earnings • Aug 12First quarter 2026 earnings released: EPS: ₹0.40 (vs ₹0.40 in 1Q 2025)First quarter 2026 results: EPS: ₹0.40 (in line with 1Q 2025). Revenue: ₹71.9m (down 13% from 1Q 2025). Net income: ₹2.70m (down 2.2% from 1Q 2025). Profit margin: 3.8% (up from 3.3% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 09Phaarmasia Limited to Report Q1, 2026 Results on Aug 11, 2025Phaarmasia Limited announced that they will report Q1, 2026 results on Aug 11, 2025Reported Earnings • May 29Full year 2025 earnings released: ₹2.33 loss per share (vs ₹0.76 loss in FY 2024)Full year 2025 results: ₹2.33 loss per share (further deteriorated from ₹0.76 loss in FY 2024). Revenue: ₹251.2m (down 18% from FY 2024). Net loss: ₹15.9m (loss widened 207% from FY 2024). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • May 23Phaarmasia Limited to Report Q4, 2025 Results on May 28, 2025Phaarmasia Limited announced that they will report Q4, 2025 results on May 28, 2025Reported Earnings • Feb 18Third quarter 2025 earnings released: ₹1.02 loss per share (vs ₹0.83 loss in 3Q 2024)Third quarter 2025 results: ₹1.02 loss per share (further deteriorated from ₹0.83 loss in 3Q 2024). Revenue: ₹49.1m (down 3.4% from 3Q 2024). Net loss: ₹6.99m (loss widened 24% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 11Phaarmasia Limited to Report Q3, 2025 Results on Feb 14, 2025Phaarmasia Limited announced that they will report Q3, 2025 results on Feb 14, 2025New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹317.0m market cap, or US$3.75m). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Revenue is less than US$5m (₹293m revenue, or US$3.5m).New Risk • Nov 06New major risk - Revenue and earnings growthEarnings have declined by 46% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹353.4m market cap, or US$4.20m). Minor Risk Revenue is less than US$5m (₹293m revenue, or US$3.5m).Reported Earnings • Nov 06Second quarter 2025 earnings released: ₹0.94 loss per share (vs ₹0.24 loss in 2Q 2024)Second quarter 2025 results: ₹0.94 loss per share (further deteriorated from ₹0.24 loss in 2Q 2024). Revenue: ₹61.5m (down 29% from 2Q 2024). Net loss: ₹6.42m (loss widened 295% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 01Phaarmasia Limited to Report Q2, 2025 Results on Nov 05, 2024Phaarmasia Limited announced that they will report Q2, 2025 results on Nov 05, 2024お知らせ • Sep 02Phaarmasia Limited, Annual General Meeting, Sep 24, 2024Phaarmasia Limited, Annual General Meeting, Sep 24, 2024, at 14:30 Indian Standard Time.Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.40 (vs ₹0.39 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.40 (up from ₹0.39 loss in 1Q 2024). Revenue: ₹84.4m (up 23% from 1Q 2024). Net income: ₹2.76m (up ₹5.42m from 1Q 2024). Profit margin: 3.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 06Phaarmasia Limited to Report Q1, 2025 Results on Aug 12, 2024Phaarmasia Limited announced that they will report Q1, 2025 results on Aug 12, 2024Reported Earnings • May 27Full year 2024 earnings released: ₹0.76 loss per share (vs ₹1.84 loss in FY 2023)Full year 2024 results: ₹0.76 loss per share (improved from ₹1.84 loss in FY 2023). Revenue: ₹312.5m (up 14% from FY 2023). Net loss: ₹5.18m (loss narrowed 59% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has remained flat, which means it is well ahead of earnings.お知らせ • May 19Phaarmasia Limited to Report Q4, 2024 Results on May 25, 2024Phaarmasia Limited announced that they will report Q4, 2024 results at 12:15 PM, Indian Standard Time on May 25, 2024New Risk • Apr 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹9.5m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 59% per year over the past 5 years. Market cap is less than US$10m (₹272.9m market cap, or US$3.27m). Minor Risk Revenue is less than US$5m (₹281m revenue, or US$3.4m).Reported Earnings • Feb 14Third quarter 2024 earnings released: ₹0.83 loss per share (vs ₹0.87 loss in 3Q 2023)Third quarter 2024 results: ₹0.83 loss per share (improved from ₹0.87 loss in 3Q 2023). Revenue: ₹52.1m (down 34% from 3Q 2023). Net loss: ₹5.64m (loss narrowed 4.6% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.お知らせ • Feb 06Phaarmasia Limited to Report Q3, 2024 Results on Feb 13, 2024Phaarmasia Limited announced that they will report Q3, 2024 results on Feb 13, 2024Reported Earnings • Nov 18Second quarter 2024 earnings released: ₹0.24 loss per share (vs ₹0.43 loss in 2Q 2023)Second quarter 2024 results: ₹0.24 loss per share (improved from ₹0.43 loss in 2Q 2023). Revenue: ₹88.4m (up 33% from 2Q 2023). Net loss: ₹1.63m (loss narrowed 44% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.New Risk • Nov 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Market cap is less than US$10m (₹172.2m market cap, or US$2.07m). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m).お知らせ • Nov 08Phaarmasia Limited to Report Q2, 2024 Results on Nov 14, 2023Phaarmasia Limited announced that they will report Q2, 2024 results on Nov 14, 2023Reported Earnings • Aug 16First quarter 2024 earnings released: ₹0.39 loss per share (vs ₹0.42 loss in 1Q 2023)First quarter 2024 results: ₹0.39 loss per share (improved from ₹0.42 loss in 1Q 2023). Revenue: ₹70.2m (up 31% from 1Q 2023). Net loss: ₹2.65m (loss narrowed 6.7% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 16First quarter 2024 earnings released: ₹0.39 loss per share (vs ₹0.42 loss in 1Q 2023)First quarter 2024 results: ₹0.39 loss per share (improved from ₹0.42 loss in 1Q 2023). Revenue: ₹70.2m (up 31% from 1Q 2023). Net loss: ₹2.65m (loss narrowed 6.7% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.お知らせ • Aug 08Phaarmasia Limited to Report Q1, 2024 Results on Aug 14, 2023Phaarmasia Limited announced that they will report Q1, 2024 results on Aug 14, 2023Reported Earnings • Jul 10Full year 2023 earnings released: ₹1.84 loss per share (vs ₹2.27 loss in FY 2022)Full year 2023 results: ₹1.84 loss per share (improved from ₹2.27 loss in FY 2022). Revenue: ₹274.9m (up 60% from FY 2022). Net loss: ₹12.6m (loss narrowed 19% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.Buying Opportunity • Jul 04Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 9.8%. The fair value is estimated to be ₹29.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.お知らせ • Jun 14Phaarmasia Limited, Annual General Meeting, Jul 10, 2023Phaarmasia Limited, Annual General Meeting, Jul 10, 2023.お知らせ • May 19Phaarmasia Limited to Report Q4, 2023 Results on May 25, 2023Phaarmasia Limited announced that they will report Q4, 2023 results on May 25, 2023Reported Earnings • Feb 15Third quarter 2023 earnings released: ₹0.87 loss per share (vs ₹1.07 loss in 3Q 2022)Third quarter 2023 results: ₹0.87 loss per share (improved from ₹1.07 loss in 3Q 2022). Revenue: ₹80.6m (up 108% from 3Q 2022). Net loss: ₹5.91m (loss narrowed 19% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 142 percentage points per year, which is a significant difference in performance.お知らせ • Feb 14Phaarmasia Limited to Report Q3, 2023 Results on Feb 13, 2023Phaarmasia Limited announced that they will report Q3, 2023 results on Feb 13, 2023Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Ajit Jamkhandikar was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Nov 08Phaarmasia Limited to Report Q2, 2023 Results on Nov 14, 2022Phaarmasia Limited announced that they will report Q2, 2023 results on Nov 14, 2022お知らせ • Sep 07Phaarmasia Limited, Annual General Meeting, Sep 27, 2022Phaarmasia Limited, Annual General Meeting, Sep 27, 2022, at 16:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Financial Statements of the company for the financial year ended 31st March, 2022, along with Notes, the Reports of the Board of Directors and the Auditors thereon; to appoint directors; to reappoint M/s. Sathuluri& Co., Chartered Accountants (Firm Registration No. 006383S)as statutory auditors of the Company; and to discuss other matters.お知らせ • Aug 03Phaarmasia Limited to Report Q1, 2023 Results on Aug 12, 2022Phaarmasia Limited announced that they will report Q1, 2023 results on Aug 12, 2022お知らせ • May 21Phaarmasia Limited to Report Q4, 2022 Results on May 27, 2022Phaarmasia Limited announced that they will report Q4, 2022 results on May 27, 2022Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Ajit Jamkhandikar was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 12Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹1.07 loss per share (down from ₹0.04 profit in 3Q 2021). Revenue: ₹39.5m (down 18% from 3Q 2021). Net loss: ₹7.28m (down ₹7.54m from profit in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.お知らせ • Feb 04Phaarmasia Limited to Report Q3, 2022 Results on Feb 10, 2022Phaarmasia Limited announced that they will report Q3, 2022 results on Feb 10, 2022Reported Earnings • Nov 11Second quarter 2022 earnings released: ₹1.04 loss per share (vs ₹0.12 profit in 2Q 2021)The company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2022 results: Revenue: ₹54.5m (up 22% from 2Q 2021). Net loss: ₹7.10m (down ₹7.93m from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Oct 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹33.45, the stock trades at a trailing P/E ratio of 76.8x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 94% over the past three years.Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹30.60, the stock trades at a trailing P/E ratio of 70.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 43% over the past three years.Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 26% share price gain to ₹30.70, the stock trades at a trailing P/E ratio of 69.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹31.55, the stock trades at a trailing P/E ratio of 68.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total loss to shareholders of 6.8% over the past three years.Reported Earnings • Jun 29Full year 2021 earnings released: EPS ₹0.46 (vs ₹0.79 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹207.9m (down 15% from FY 2020). Net income: ₹3.12m (down 42% from FY 2020). Profit margin: 1.5% (down from 2.2% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 03Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹33.00, the stock trades at a trailing P/E ratio of 35.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 100% over the past year.Valuation Update With 7 Day Price Move • May 05Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹36.75, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total loss to shareholders of 1.9% over the past three years.Valuation Update With 7 Day Price Move • Mar 26Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹23.50, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in India. Total loss to shareholders of 36% over the past three years.Reported Earnings • Feb 17Third quarter 2021 earnings released: EPS ₹0.04 (vs ₹0.02 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₹48.2m (down 29% from 3Q 2020). Net income: ₹255.0k (up 104% from 3Q 2020). Profit margin: 0.5% (up from 0.2% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Feb 05Phaarmasia Limited to Report Q3, 2021 Results on Feb 12, 2021Phaarmasia Limited announced that they will report Q3, 2021 results on Feb 12, 2021Is New 90 Day High Low • Dec 29New 90-day high: ₹33.30The company is up 20% from its price of ₹27.65 on 30 September 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹33.30, the stock is trading at a trailing P/E ratio of 35.5x, up from the previous P/E ratio of 30.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 25%.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹27.15, the stock is trading at a trailing P/E ratio of 29x, up from the previous P/E ratio of 25.1x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total return to shareholders over the past three years is a loss of 11%.Is New 90 Day High Low • Nov 24New 90-day low: ₹24.70The company is down 36% from its price of ₹38.40 on 26 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.株主還元523620IN PharmaceuticalsIN 市場7D-3.3%-0.3%-0.4%1Y176.4%16.1%4.6%株主還元を見る業界別リターン: 523620過去 1 年間で16.1 % の収益を上げたIndian Pharmaceuticals業界を上回りました。リターン対市場: 523620過去 1 年間で4.6 % の収益を上げたIndian市場を上回りました。価格変動Is 523620's price volatile compared to industry and market?523620 volatility523620 Average Weekly Movement9.5%Pharmaceuticals Industry Average Movement6.0%Market Average Movement5.9%10% most volatile stocks in IN Market9.0%10% least volatile stocks in IN Market3.6%安定した株価: 523620の株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 523620の weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてIndianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト198136Yallapragada Naga Raowww.phaarmasia.inファルマシア社はインドで経口避妊薬と鉄剤を製造・販売している。同社は、ミフェプリストンとミソプロスタオール、デソゲストレルとエチニルエストラジオール、エストラジオールバレレート、レボノルゲストレルとエチニルエストラジオール、酢酸メドロキシプロゲステロン、カベルゴリン、クエン酸クロミフェン、レボノルゲストレルなどのホルモン製品を提供している、プロゲステロン、フルオキシメステロン、リオチロニンナトリウム、クロロデヒドロメチルテストステロン、リオチロニンナトリウム、オキサンドロロン錠、テストステロンシピオネート、メテノロンエナント酸、ドロスタノロン、テストステロン、トレンボロン、スタノゾロールシピオネート注射。Smyleのブランド名で、ハーブ歯磨き粉、咳止め・喉の痛み止め、口内炎ジェルなどのハーブ製品を提供している。ファルマシア社は1981年に設立され、インドのハイデラバードに本社を置く。もっと見るPhaarmasia Limited 基礎のまとめPhaarmasia の収益と売上を時価総額と比較するとどうか。523620 基礎統計学時価総額₹523.15m収益（TTM）₹176.42m売上高(TTM)₹486.03m3.0xPER（株価収益率1.1xP/Sレシオ523620 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計523620 損益計算書（TTM）収益₹486.03m売上原価₹344.74m売上総利益₹141.30mその他の費用-₹35.12m収益₹176.42m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）25.84グロス・マージン29.07%純利益率36.30%有利子負債／自己資本比率5.1%523620 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/17 00:41終値2026/08/17 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Phaarmasia Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Aug 15First quarter 2027 earnings released: EPS: ₹0.50 (vs ₹0.40 in 1Q 2026)First quarter 2027 results: EPS: ₹0.50 (up from ₹0.40 in 1Q 2026). Revenue: ₹85.8m (up 25% from 1Q 2026). Net income: ₹3.39m (up 26% from 1Q 2026). Profit margin: 3.9% (in line with 1Q 2026). Over the last 3 years on average, earnings per share has increased by 130% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.
New Risk • Aug 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (327% accrual ratio). Market cap is less than US$10m (₹582.3m market cap, or US$6.10m). Minor Risk Revenue is less than US$5m (₹472m revenue, or US$4.9m).
お知らせ • Aug 10Phaarmasia Limited to Report Q1, 2027 Results on Aug 13, 2026Phaarmasia Limited announced that they will report Q1, 2027 results on Aug 13, 2026
New Risk • Jun 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (327% accrual ratio). Market cap is less than US$10m (₹750.7m market cap, or US$7.88m). Minor Risk Revenue is less than US$5m (₹472m revenue, or US$5.0m).
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹91.85, the stock trades at a trailing P/E ratio of 3.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 254% over the past three years.
Reported Earnings • May 31Full year 2026 earnings released: EPS: ₹25.74 (vs ₹2.33 loss in FY 2025)Full year 2026 results: EPS: ₹25.74 (up from ₹2.33 loss in FY 2025). Revenue: ₹481.7m (up 98% from FY 2025). Net income: ₹175.7m (up ₹191.6m from FY 2025). Profit margin: 37% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 132% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 15First quarter 2027 earnings released: EPS: ₹0.50 (vs ₹0.40 in 1Q 2026)First quarter 2027 results: EPS: ₹0.50 (up from ₹0.40 in 1Q 2026). Revenue: ₹85.8m (up 25% from 1Q 2026). Net income: ₹3.39m (up 26% from 1Q 2026). Profit margin: 3.9% (in line with 1Q 2026). Over the last 3 years on average, earnings per share has increased by 130% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.
New Risk • Aug 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (327% accrual ratio). Market cap is less than US$10m (₹582.3m market cap, or US$6.10m). Minor Risk Revenue is less than US$5m (₹472m revenue, or US$4.9m).
お知らせ • Aug 10Phaarmasia Limited to Report Q1, 2027 Results on Aug 13, 2026Phaarmasia Limited announced that they will report Q1, 2027 results on Aug 13, 2026
New Risk • Jun 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (327% accrual ratio). Market cap is less than US$10m (₹750.7m market cap, or US$7.88m). Minor Risk Revenue is less than US$5m (₹472m revenue, or US$5.0m).
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹91.85, the stock trades at a trailing P/E ratio of 3.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 254% over the past three years.
Reported Earnings • May 31Full year 2026 earnings released: EPS: ₹25.74 (vs ₹2.33 loss in FY 2025)Full year 2026 results: EPS: ₹25.74 (up from ₹2.33 loss in FY 2025). Revenue: ₹481.7m (up 98% from FY 2025). Net income: ₹175.7m (up ₹191.6m from FY 2025). Profit margin: 37% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 132% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.
お知らせ • May 22Phaarmasia Limited to Report Q4, 2026 Results on May 29, 2026Phaarmasia Limited announced that they will report Q4, 2026 results on May 29, 2026
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹93.49, the stock trades at a trailing P/E ratio of 3.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 253% over the past three years.
New Risk • Apr 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹607.2m market cap, or US$6.56m). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₹449m revenue, or US$4.9m).
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹88.94, the stock trades at a trailing P/E ratio of 3.4x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 240% over the past three years.
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹75.20, the stock trades at a trailing P/E ratio of 2.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 209% over the past three years.
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹99.12, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 304% over the past three years.
Reported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹23.84 (vs ₹1.02 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹23.84 (up from ₹1.02 loss in 3Q 2025). Revenue: ₹162.1m (up 243% from 3Q 2025). Net income: ₹162.7m (up ₹169.7m from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 55% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 02Phaarmasia Limited to Report Q3, 2026 Results on Feb 06, 2026Phaarmasia Limited announced that they will report Q3, 2026 results on Feb 06, 2026
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improves as stock rises 33%After last week's 33% share price gain to ₹49.08, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 57% over the past three years.
Reported Earnings • Nov 16Second quarter 2026 earnings released: EPS: ₹2.54 (vs ₹0.94 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹2.54 (up from ₹0.94 loss in 2Q 2025). Revenue: ₹166.9m (up 182% from 2Q 2025). Net income: ₹17.4m (up ₹23.8m from 2Q 2025). Profit margin: 10% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 07Phaarmasia Limited to Report Q2, 2026 Results on Nov 14, 2025Phaarmasia Limited announced that they will report Q2, 2026 results on Nov 14, 2025
お知らせ • Sep 03Phaarmasia Limited, Annual General Meeting, Sep 25, 2025Phaarmasia Limited, Annual General Meeting, Sep 25, 2025, at 16:00 Indian Standard Time.
New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (₹180.9m market cap, or US$2.06m). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (₹230m revenue, or US$2.6m).
Reported Earnings • Aug 12First quarter 2026 earnings released: EPS: ₹0.40 (vs ₹0.40 in 1Q 2025)First quarter 2026 results: EPS: ₹0.40 (in line with 1Q 2025). Revenue: ₹71.9m (down 13% from 1Q 2025). Net income: ₹2.70m (down 2.2% from 1Q 2025). Profit margin: 3.8% (up from 3.3% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 09Phaarmasia Limited to Report Q1, 2026 Results on Aug 11, 2025Phaarmasia Limited announced that they will report Q1, 2026 results on Aug 11, 2025
Reported Earnings • May 29Full year 2025 earnings released: ₹2.33 loss per share (vs ₹0.76 loss in FY 2024)Full year 2025 results: ₹2.33 loss per share (further deteriorated from ₹0.76 loss in FY 2024). Revenue: ₹251.2m (down 18% from FY 2024). Net loss: ₹15.9m (loss widened 207% from FY 2024). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • May 23Phaarmasia Limited to Report Q4, 2025 Results on May 28, 2025Phaarmasia Limited announced that they will report Q4, 2025 results on May 28, 2025
Reported Earnings • Feb 18Third quarter 2025 earnings released: ₹1.02 loss per share (vs ₹0.83 loss in 3Q 2024)Third quarter 2025 results: ₹1.02 loss per share (further deteriorated from ₹0.83 loss in 3Q 2024). Revenue: ₹49.1m (down 3.4% from 3Q 2024). Net loss: ₹6.99m (loss widened 24% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 11Phaarmasia Limited to Report Q3, 2025 Results on Feb 14, 2025Phaarmasia Limited announced that they will report Q3, 2025 results on Feb 14, 2025
New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹317.0m market cap, or US$3.75m). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Revenue is less than US$5m (₹293m revenue, or US$3.5m).
New Risk • Nov 06New major risk - Revenue and earnings growthEarnings have declined by 46% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹353.4m market cap, or US$4.20m). Minor Risk Revenue is less than US$5m (₹293m revenue, or US$3.5m).
Reported Earnings • Nov 06Second quarter 2025 earnings released: ₹0.94 loss per share (vs ₹0.24 loss in 2Q 2024)Second quarter 2025 results: ₹0.94 loss per share (further deteriorated from ₹0.24 loss in 2Q 2024). Revenue: ₹61.5m (down 29% from 2Q 2024). Net loss: ₹6.42m (loss widened 295% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 01Phaarmasia Limited to Report Q2, 2025 Results on Nov 05, 2024Phaarmasia Limited announced that they will report Q2, 2025 results on Nov 05, 2024
お知らせ • Sep 02Phaarmasia Limited, Annual General Meeting, Sep 24, 2024Phaarmasia Limited, Annual General Meeting, Sep 24, 2024, at 14:30 Indian Standard Time.
Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.40 (vs ₹0.39 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.40 (up from ₹0.39 loss in 1Q 2024). Revenue: ₹84.4m (up 23% from 1Q 2024). Net income: ₹2.76m (up ₹5.42m from 1Q 2024). Profit margin: 3.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 06Phaarmasia Limited to Report Q1, 2025 Results on Aug 12, 2024Phaarmasia Limited announced that they will report Q1, 2025 results on Aug 12, 2024
Reported Earnings • May 27Full year 2024 earnings released: ₹0.76 loss per share (vs ₹1.84 loss in FY 2023)Full year 2024 results: ₹0.76 loss per share (improved from ₹1.84 loss in FY 2023). Revenue: ₹312.5m (up 14% from FY 2023). Net loss: ₹5.18m (loss narrowed 59% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
お知らせ • May 19Phaarmasia Limited to Report Q4, 2024 Results on May 25, 2024Phaarmasia Limited announced that they will report Q4, 2024 results at 12:15 PM, Indian Standard Time on May 25, 2024
New Risk • Apr 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹9.5m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 59% per year over the past 5 years. Market cap is less than US$10m (₹272.9m market cap, or US$3.27m). Minor Risk Revenue is less than US$5m (₹281m revenue, or US$3.4m).
Reported Earnings • Feb 14Third quarter 2024 earnings released: ₹0.83 loss per share (vs ₹0.87 loss in 3Q 2023)Third quarter 2024 results: ₹0.83 loss per share (improved from ₹0.87 loss in 3Q 2023). Revenue: ₹52.1m (down 34% from 3Q 2023). Net loss: ₹5.64m (loss narrowed 4.6% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
お知らせ • Feb 06Phaarmasia Limited to Report Q3, 2024 Results on Feb 13, 2024Phaarmasia Limited announced that they will report Q3, 2024 results on Feb 13, 2024
Reported Earnings • Nov 18Second quarter 2024 earnings released: ₹0.24 loss per share (vs ₹0.43 loss in 2Q 2023)Second quarter 2024 results: ₹0.24 loss per share (improved from ₹0.43 loss in 2Q 2023). Revenue: ₹88.4m (up 33% from 2Q 2023). Net loss: ₹1.63m (loss narrowed 44% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
New Risk • Nov 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Market cap is less than US$10m (₹172.2m market cap, or US$2.07m). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m).
お知らせ • Nov 08Phaarmasia Limited to Report Q2, 2024 Results on Nov 14, 2023Phaarmasia Limited announced that they will report Q2, 2024 results on Nov 14, 2023
Reported Earnings • Aug 16First quarter 2024 earnings released: ₹0.39 loss per share (vs ₹0.42 loss in 1Q 2023)First quarter 2024 results: ₹0.39 loss per share (improved from ₹0.42 loss in 1Q 2023). Revenue: ₹70.2m (up 31% from 1Q 2023). Net loss: ₹2.65m (loss narrowed 6.7% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 16First quarter 2024 earnings released: ₹0.39 loss per share (vs ₹0.42 loss in 1Q 2023)First quarter 2024 results: ₹0.39 loss per share (improved from ₹0.42 loss in 1Q 2023). Revenue: ₹70.2m (up 31% from 1Q 2023). Net loss: ₹2.65m (loss narrowed 6.7% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 08Phaarmasia Limited to Report Q1, 2024 Results on Aug 14, 2023Phaarmasia Limited announced that they will report Q1, 2024 results on Aug 14, 2023
Reported Earnings • Jul 10Full year 2023 earnings released: ₹1.84 loss per share (vs ₹2.27 loss in FY 2022)Full year 2023 results: ₹1.84 loss per share (improved from ₹2.27 loss in FY 2022). Revenue: ₹274.9m (up 60% from FY 2022). Net loss: ₹12.6m (loss narrowed 19% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.
Buying Opportunity • Jul 04Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 9.8%. The fair value is estimated to be ₹29.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Jun 14Phaarmasia Limited, Annual General Meeting, Jul 10, 2023Phaarmasia Limited, Annual General Meeting, Jul 10, 2023.
お知らせ • May 19Phaarmasia Limited to Report Q4, 2023 Results on May 25, 2023Phaarmasia Limited announced that they will report Q4, 2023 results on May 25, 2023
Reported Earnings • Feb 15Third quarter 2023 earnings released: ₹0.87 loss per share (vs ₹1.07 loss in 3Q 2022)Third quarter 2023 results: ₹0.87 loss per share (improved from ₹1.07 loss in 3Q 2022). Revenue: ₹80.6m (up 108% from 3Q 2022). Net loss: ₹5.91m (loss narrowed 19% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 142 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 14Phaarmasia Limited to Report Q3, 2023 Results on Feb 13, 2023Phaarmasia Limited announced that they will report Q3, 2023 results on Feb 13, 2023
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Ajit Jamkhandikar was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Nov 08Phaarmasia Limited to Report Q2, 2023 Results on Nov 14, 2022Phaarmasia Limited announced that they will report Q2, 2023 results on Nov 14, 2022
お知らせ • Sep 07Phaarmasia Limited, Annual General Meeting, Sep 27, 2022Phaarmasia Limited, Annual General Meeting, Sep 27, 2022, at 16:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Financial Statements of the company for the financial year ended 31st March, 2022, along with Notes, the Reports of the Board of Directors and the Auditors thereon; to appoint directors; to reappoint M/s. Sathuluri& Co., Chartered Accountants (Firm Registration No. 006383S)as statutory auditors of the Company; and to discuss other matters.
お知らせ • Aug 03Phaarmasia Limited to Report Q1, 2023 Results on Aug 12, 2022Phaarmasia Limited announced that they will report Q1, 2023 results on Aug 12, 2022
お知らせ • May 21Phaarmasia Limited to Report Q4, 2022 Results on May 27, 2022Phaarmasia Limited announced that they will report Q4, 2022 results on May 27, 2022
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Ajit Jamkhandikar was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 12Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹1.07 loss per share (down from ₹0.04 profit in 3Q 2021). Revenue: ₹39.5m (down 18% from 3Q 2021). Net loss: ₹7.28m (down ₹7.54m from profit in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
お知らせ • Feb 04Phaarmasia Limited to Report Q3, 2022 Results on Feb 10, 2022Phaarmasia Limited announced that they will report Q3, 2022 results on Feb 10, 2022
Reported Earnings • Nov 11Second quarter 2022 earnings released: ₹1.04 loss per share (vs ₹0.12 profit in 2Q 2021)The company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2022 results: Revenue: ₹54.5m (up 22% from 2Q 2021). Net loss: ₹7.10m (down ₹7.93m from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Oct 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹33.45, the stock trades at a trailing P/E ratio of 76.8x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 94% over the past three years.
Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹30.60, the stock trades at a trailing P/E ratio of 70.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 43% over the past three years.
Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 26% share price gain to ₹30.70, the stock trades at a trailing P/E ratio of 69.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹31.55, the stock trades at a trailing P/E ratio of 68.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total loss to shareholders of 6.8% over the past three years.
Reported Earnings • Jun 29Full year 2021 earnings released: EPS ₹0.46 (vs ₹0.79 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹207.9m (down 15% from FY 2020). Net income: ₹3.12m (down 42% from FY 2020). Profit margin: 1.5% (down from 2.2% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 03Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹33.00, the stock trades at a trailing P/E ratio of 35.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 100% over the past year.
Valuation Update With 7 Day Price Move • May 05Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹36.75, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total loss to shareholders of 1.9% over the past three years.
Valuation Update With 7 Day Price Move • Mar 26Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹23.50, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in India. Total loss to shareholders of 36% over the past three years.
Reported Earnings • Feb 17Third quarter 2021 earnings released: EPS ₹0.04 (vs ₹0.02 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₹48.2m (down 29% from 3Q 2020). Net income: ₹255.0k (up 104% from 3Q 2020). Profit margin: 0.5% (up from 0.2% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Feb 05Phaarmasia Limited to Report Q3, 2021 Results on Feb 12, 2021Phaarmasia Limited announced that they will report Q3, 2021 results on Feb 12, 2021
Is New 90 Day High Low • Dec 29New 90-day high: ₹33.30The company is up 20% from its price of ₹27.65 on 30 September 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹33.30, the stock is trading at a trailing P/E ratio of 35.5x, up from the previous P/E ratio of 30.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 25%.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹27.15, the stock is trading at a trailing P/E ratio of 29x, up from the previous P/E ratio of 25.1x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total return to shareholders over the past three years is a loss of 11%.
Is New 90 Day High Low • Nov 24New 90-day low: ₹24.70The company is down 36% from its price of ₹38.40 on 26 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
